Body Composition and Fatty Liver Disease

Study Overview
=================
Brief Summary
-----------------
This study investigates relationship between fatty liver prognosis and body composition analysis result based on non-contrast low dose CT in patients with fatty liver disease.

Official Title
-----------------
Analysis of the Prognostic Correlation Between Body Composition Analysis and Fatty Liver Progression in Patients With Fatty Liver Using Low-dose CT

Conditions
-----------------
Fatty Liver

Intervention / Treatment
-----------------
* Diagnostic Test: Non-contrast low-dose abdomen CT
* Diagnostic Test: Fibroscan
* Diagnostic Test: bioelectrical impedance analysis (BIA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: metabolic dysfunction-associated fatty liver disease (fatty liver with overweight/obesity, or type II DM or other metabolic dysfunction) or non-alcoholic fatty liver disease with liver function test abnormality signed informed consent Exclusion Criteria: chronic hepatitis B or C other disease related to fatty liver such as glycogen storage disease, lipodystrophy, familial combined hyperlipidemia, hypobetalipoproteinemia, Weber-Christian syndrome or abetalipoproteinemia on medication related to hepatic steatosis (tamoxifen, steroid, valproic acid, methotrexate, amiodarone) diabetes after pancreatectomy history of total parenteral nutrition in 6 months pregnancy or nursing mother

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: non-contrast low-dose abdomen CT<br>non-contrast low-dose abdomen CT (target effective dose: < 1.5 mSv). CT based body composition analysis is performedd with commercially available automatic segmentation software (DeepCatch, Medical IP, South Korea). | Diagnostic Test: Non-contrast low-dose abdomen CT<br>* target effective dose: < 1.5 mSv It is performed twice in 6-month interval.<br>Diagnostic Test: Fibroscan<br>* Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.<br>Diagnostic Test: bioelectrical impedance analysis (BIA)<br>* BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.<br>* Other names: Inbody test (commercial name);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| relationship between body composition analysis result from CT and liver fat fraction | relationship between visceral fat volume fraction (obtained from CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and CAP value of fibroscan | 6 month after CT acquisition | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ratio of appropriate non-contrast low dose abdomen CT acquisition & analysis | Number of CT scan with effective dose < 1.5 mSv AND successful automatic body composition analysis (without manual editing) divided by total number of CT scan | 6 month after CT acquisition | 
| relationship between body composition analysis result from CT and hepatic fibrosis | relationship between visceral fat volume fraction (CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and liver stiffness value of fibroscan | 6 month after CT acquisition | 
| agreement between body composition analysis result from CT and bioelectrical impedance analysis (Inbody test) | agreement of visceral fat, subcutaneous fat, muscle amount between CT based body composition and Inbody test results | 6 month after CT acquisition | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CT